Collegium Pharmaceutical Inc (NASDAQ:COLL) – Stock analysts at Gabelli dropped their FY2017 earnings per share estimates for Collegium Pharmaceutical in a research report issued on Thursday. Gabelli analyst K. Kedra now anticipates that the brokerage will post earnings per share of ($3.10) for the year, down from their previous forecast of ($3.05). Gabelli also issued estimates for Collegium Pharmaceutical’s FY2019 earnings at ($0.85) EPS.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.05. WARNING: This article was published by Mideast Time and is the property of of Mideast Time. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.mideasttime.com/gabelli-comments-on-collegium-pharmaceutical-incs-fy2017-earnings-coll/1588792.html.
A number of other brokerages have also issued reports on COLL. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 11th. Jefferies Group LLC set a $24.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.80.
Collegium Pharmaceutical (NASDAQ:COLL) opened at 11.31 on Monday. The company has a 50-day moving average price of $14.78 and a 200-day moving average price of $15.50. Collegium Pharmaceutical has a 52 week low of $8.24 and a 52 week high of $20.55. The stock’s market cap is $333.06 million.
Several hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. increased its stake in shares of Collegium Pharmaceutical by 98.2% in the fourth quarter. Franklin Resources Inc. now owns 1,797,902 shares of the specialty pharmaceutical company’s stock valued at $27,994,000 after buying an additional 890,868 shares during the period. Cadian Capital Management LP bought a new stake in shares of Collegium Pharmaceutical during the third quarter valued at approximately $9,248,000. Sectoral Asset Management Inc increased its stake in shares of Collegium Pharmaceutical by 139.8% in the third quarter. Sectoral Asset Management Inc now owns 705,845 shares of the specialty pharmaceutical company’s stock valued at $13,595,000 after buying an additional 411,445 shares during the period. Highland Capital Management LP increased its stake in shares of Collegium Pharmaceutical by 109.8% in the fourth quarter. Highland Capital Management LP now owns 684,909 shares of the specialty pharmaceutical company’s stock valued at $10,664,000 after buying an additional 358,409 shares during the period. Finally, Rock Springs Capital Management LP increased its stake in shares of Collegium Pharmaceutical by 27.2% in the third quarter. Rock Springs Capital Management LP now owns 1,545,000 shares of the specialty pharmaceutical company’s stock valued at $29,757,000 after buying an additional 330,000 shares during the period. 56.60% of the stock is currently owned by institutional investors and hedge funds.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.